Shionogi Pharmaceutical Co., Ltd. announced an interim report of a clinical trial assuming the use of a new coronavirus vaccine under development for booster vaccination, and confirmed the same effect as the Pfizer vaccine in terms of neutralizing antibody values ​​and the like. I tried.

Shionogi Pharmaceutical Co., Ltd., headquartered in Osaka, announced on the 4th an interim report of a clinical trial assuming booster vaccination for a new type of corona vaccine called "recombinant protein vaccine" that is under development.



In clinical trials, about 200 people who had been vaccinated twice with Pfizer vaccine for more than half a year were re-vaccinated with Pfizer vaccine as a booster vaccination, and when they were vaccinated with the vaccine under development, the efficacy and safety were improved. I investigated if there was a difference.



As a result so far, when comparing the values ​​of neutralizing antibodies on the 29th day after vaccination, the number of people who received the vaccine under development was 1.17 times that of those who received the Pfizer vaccine, which is statistics. It means that it was confirmed that they were at the same level.



Regarding side reactions, pain and malaise at the site of inoculation, as well as myalgia and fever were reported, but none were serious and were equal to or less than Pfizer's vaccine.

At the press conference, Isao Teshiroki, president of Shionogi Pharmaceutical Co., Ltd., said, "It's a very good result. I think this data is very strong and valuable."